Moly

Almonty Closes Additional Tranches of Private Placement

Retrieved on: 
Saturday, April 20, 2024
Mining, Minerals, Natural Resources, Tungsten, Sale, Moly, Person, ALI, News, Risk, Private, CDN, TSX, Multilateral, UPDATE, ANY, AII, Acquisition, APT, THIS, Minority, CDI, Placement

Lewis Black, Mark Trachuk, Daniel D’Amato and Andrew Ryu (the “Insiders”) participated in the private placement and, as such, the private placement is considered a related party transaction within the meaning of Multilateral Instrument 61-101– Protection of Minority Security Holders in Special Transactions (“MI 61-101”).

Key Points: 
  • Lewis Black, Mark Trachuk, Daniel D’Amato and Andrew Ryu (the “Insiders”) participated in the private placement and, as such, the private placement is considered a related party transaction within the meaning of Multilateral Instrument 61-101– Protection of Minority Security Holders in Special Transactions (“MI 61-101”).
  • The Los Santos Mine was acquired by Almonty in September 2011 and is located approximately 50 kilometres from Salamanca in western Spain and produces tungsten concentrate.
  • Almonty has also assumed that material factors will not cause any forward-looking statements and information to differ materially from actual results or events.
  • WHILE ALMONTY MAY ELECT TO, IT DOES NOT UNDERTAKE TO UPDATE THIS INFORMATION AT ANY PARTICULAR TIME EXCEPT AS REQUIRED IN ACCORDANCE WITH APPLICABLE LAWS.

Almonty Industries Inc. - Placement of Common Share Units and CDI’s raises C$1.47 million1 with Further Commitments of C$1.178 million for acceleration of Tungsten downstream planning and Molybdenum reserves conversion.

Retrieved on: 
Saturday, March 23, 2024
Finance, Natural Resources, Professional Services, Other Natural Resources, Mining, Minerals, Indian stock exchange, Private placement, ANY, Private, CDI, APT, Minority, Risk, ASX, Sale, Acquisition, Placement, Lead, THIS, Tungsten, Moly, TSX, AII, ALI, Multilateral, UPDATE, Person

Proceeds from the Placement will be applied towards general working capital, including accelerating the downstream project planning and further investigation of the Moly due to increasing interest in the material domestically.

Key Points: 
  • Proceeds from the Placement will be applied towards general working capital, including accelerating the downstream project planning and further investigation of the Moly due to increasing interest in the material domestically.
  • The Placement Units and Placement CDI’s issued will rank equally with existing CDI’s and Common Shares on issue.
  • The closing of the CDI Placement is subject to receipt of all necessary regulatory approvals, including the acceptance by the TSX and ASX.
  • READERS SHOULD NOT PLACE UNDUE IMPORTANCE ON FORWARD- LOOKING INFORMATION AND SHOULD NOT RELY UPON THIS INFORMATION AS OF ANY OTHER DATE.

Almonty Announces Receipt of the First Drawdown Amount of US$12,818,081 With the Next Drawdown of US$4,840,524 Now Scheduled for August 11, 2022

Retrieved on: 
Thursday, July 28, 2022
Mining, Minerals, Natural Resources, TSX, Acquisition, Sale, Knowledge, TSC Industries, Inc. v. Northway, Inc., ANY, Molybdenum, ALI, Forward-looking statement, Person, APT, Risk, THE, Tungsten, Mining, IS, OF, Company, THIS, Los Santos mine, Terminology, UPDATE, Growth, AII, Renewable energy, Risk management, Panasqueira, Almonty Industries, Moly

Our Sangdong mine will secure Western supply of the critical metal tungsten for many decades to come.

Key Points: 
  • Our Sangdong mine will secure Western supply of the critical metal tungsten for many decades to come.
  • Our Moly project also presents some unique domestic supply chain opportunities and will be well supported in-country.
  • READERS SHOULD NOT PLACE UNDUE IMPORTANCE ON FORWARD-LOOKING INFORMATION AND SHOULD NOT RELY UPON THIS INFORMATION AS OF ANY OTHER DATE.
  • WHILE ALMONTY MAY ELECT TO, IT DOES NOT UNDERTAKE TO UPDATE THIS INFORMATION AT ANY PARTICULAR TIME EXCEPT AS REQUIRED IN ACCORDANCE WITH APPLICABLE LAWS.

ImmunoGen Presents Full Results from Positive Pivotal SORAYA Trial of Mirvetuximab Soravtansine in Ovarian Cancer at SGO Annual Meeting

Retrieved on: 
Saturday, March 19, 2022
Biotechnology, FDA, Other Health, Health, Pharmaceutical, Oncology, Medical Devices, Research, Hospitals, Science, Clinical Trials, BLA, IMGN, Dana–Farber Cancer Institute, ImmunoGen, Progression-free survival, Neoplasm, Cleavage, ASCO, Time, Neoadjuvant therapy, Annual report, Security (finance), ADC, ORR, EDT, Bevacizumab, Nausea, Senior, Moly, View, Industry, Annual general meeting, Harvard Medical School, U.S. Securities and Exchange Commission, PARP, Toxicity, Genta (company), Safety, Investor, DOR, ID, Society, CRS, Program, McGovern Medical School, Ovarian cancer, Gynecologic Oncology (journal), Society of Gynecologic Oncology, SGO, FDA, Company, Parpi, Cancer, PFS, Hoffmann-La Roche, Control, COVID-19, Carboplatin, Physician, Division, Pharmaceutical industry, Vaccine, MD, Medicine, Genentech, Patient

The results are being presented by Dr. Ursula Matulonis in the late-breaking abstract plenary session on Saturday, March 19 at the Society of Gynecologic Oncology (SGO) 2022 Annual Meeting in Phoenix, AZ.

Key Points: 
  • The results are being presented by Dr. Ursula Matulonis in the late-breaking abstract plenary session on Saturday, March 19 at the Society of Gynecologic Oncology (SGO) 2022 Annual Meeting in Phoenix, AZ.
  • The study is designed to rule out a 12% ORR, based on expected outcomes of 4% to 13% with available single agent chemotherapy.
  • Mirvetuximab was well-tolerated, consistent with the known safety profile seen in more than 700 patients treated in the broader mirvetuximab program.
  • We are thrilled with the SORAYA results, which are remarkably consistent with data previously generated with mirvetuximab in a heavily-pretreated population of platinum-resistant ovarian cancer patients that included prior exposure to bevacizumab.

ImmunoGen to Present Full Results from SORAYA Trial of Mirvetuximab Soravtansine in Ovarian Cancer at the Society of Gynecologic Oncology Annual Meeting

Retrieved on: 
Thursday, March 10, 2022
Oncology, Health, General Health, Clinical Trials, Research, Science, Biotechnology, Therapy, ImmunoGen, Industry, EDT, Safety, ASCO, McGovern Medical School, Obstetrics, Randomness, Company, Gynecologic Oncology (journal), U.S. Securities and Exchange Commission, Annual report, SGO, Cancer, View, Gynaecology, Investor, Dana–Farber Cancer Institute, University, Fallopian tube cancer, IMGN, Intellectual property, Society, Ovarian cancer, Folate, Security (finance), 2021 Essex County Council election, Society of Gynecologic Oncology, University of Oklahoma College of Medicine, Harvard Medical School, Duke University School of Medicine, Moly, COVID-19, Genta (company), Control, Positive, Division, Northern Oklahoma College, ID, Associate, Vaccine, Birth control, Dietary supplement, Management, Pharmaceutical industry, Carboplatin, Patient, Medicine, Bevacizumab

Full results from the pivotal SORAYA trial of mirvetuximab soravtansine (mirvetuximab) in ovarian cancer will be shared in a late-breaking oral presentation.

Key Points: 
  • Full results from the pivotal SORAYA trial of mirvetuximab soravtansine (mirvetuximab) in ovarian cancer will be shared in a late-breaking oral presentation.
  • To access the live event by phone, dial (877) 621-5803; the conference ID is 1986619.
  • The event may also be accessed via webstream on the Investors and Media section of the Companys website, www.immunogen.com .
  • ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients.

RevoluGROUP Canada Inc. Divests its Pidgeon Molybdenum Property in Ontario for CAD 100,000 while Retaining a 2% NSR

Retrieved on: 
Thursday, May 20, 2021
Pidgeon, Moly, Revo

Pidgeon Moly is the legal and beneficial owner of a 100% interest in and to the Pidgeon Molybdenum Property, located in the Province of Ontario (the "Property").

Key Points: 
  • Pidgeon Moly is the legal and beneficial owner of a 100% interest in and to the Pidgeon Molybdenum Property, located in the Province of Ontario (the "Property").
  • The redundant Pidgeon Molybdenum legacy resource assets have no intrinsic connection to the Company\'s direction over the previous five years, nor our future.
  • In addition, retaining NSR royalties for our shareholders should ensure the Company with ongoing revenue from an essentially dormant asset that may otherwise have provided zero returns.
  • Click here to read more.\nFor further information on RevoluGROUP Canada Inc. (TSX-V: REVO), visit the Company\'s website at www.RevoluGROUP.com .

Global Molybdenum Disulfide (MoS2) Market Analysis and Forecasts to 2025 - ResearchAndMarkets.com

Retrieved on: 
Friday, June 12, 2020
Chemicals, Plastics, Manufacturing, Companies, Chemistry, Physical sciences, Molybdenum, Moly, Rio Tinto, Freeport-McMoRan, Molybdenum mining in the United States

The "Molybdenum Disulfide (MoS2) Market - Growth, Trends, and Forecast (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Molybdenum Disulfide (MoS2) Market - Growth, Trends, and Forecast (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering.
  • The market molybdenum disulfide is expected to grow at a CAGR of more than 4% during the forecast period.
  • Major factors driving the market studied are increasing steel production, growing demand from the energy sector.
  • Some of the major players in the market include Anglo American, Rio Tinto, Freeport-McMoRan, MOLTUN, and Antofagasta plc, among others.

Molybdenum Industry Forecasts to 2025: Global Market Size & Share, Production and Consumption

Retrieved on: 
Monday, February 17, 2020
Chemistry, Physical sciences, Natural sciences, Molybdenum, Rio Tinto, Steel industry in China, Moly, Compound annual growth rate, Molybdenum mining in the United States

The global molybdenum market is estimated to witness a healthy growth, at an estimated CAGR of around 4%, over the forecast period.

Key Points: 
  • The global molybdenum market is estimated to witness a healthy growth, at an estimated CAGR of around 4%, over the forecast period.
  • Increasing steel production in china and growing demand from the energy sector are expected to drive the market growth.
  • The global molybdenum market is a consolidated market, with the top players accounting for a major chunk of the market.
  • Key players in the molybdenum market include Anglo American, Antofagasta plc, China Molybdenum Co. Ltd, Grupo Mexico, and Rio Tinto, among others.

Compass Minerals Plant Nutrition Adds Seed Finisher with Micronutrients to Rocket Seeds™ Portfolio

Retrieved on: 
Monday, December 9, 2019
Chemicals, Plastics, Natural Resources, Manufacturing, Mining, Minerals, Articles, Academic disciplines, Compass Minerals, Plants, Plant nutrition, Micronutrient, Seed, Nutrition, Moly

Compass Minerals Plant Nutrition, a business unit of Compass Minerals , today announced the launch of Rocket Seeds Moly Shine, a unique seed finisher with the added benefit of micronutrients.

Key Points: 
  • Compass Minerals Plant Nutrition, a business unit of Compass Minerals , today announced the launch of Rocket Seeds Moly Shine, a unique seed finisher with the added benefit of micronutrients.
  • Rocket Seeds is a portfolio of dry and liquid seed nutrition, with patent-pending products that launched earlier this year.
  • Moly Shine is a key addition to our Rocket Seeds portfolio, said Dr. Ryan Bartlett, vice president, innovation and product development.
  • Through extensive research and development, Compass Minerals Plant Nutrition is dedicated to developing new technologies, like Rocket Seeds Moly Shine, to ensure availability of high quality nutrients for every plant, at every crop stage, across every acre.

$5+ Billion Molybdenum Market - Global Forecasts from 2019 to 2024 - ResearchAndMarkets.com

Retrieved on: 
Friday, July 12, 2019
Mining, Minerals, Natural Resources, Chemistry, Physical sciences, Natural sciences, Chemical elements, Refractory metals, Transition metals, Dietary minerals, Molybdenum, Moly, Tungsten, Boron

The "Global Molybdenum Market - Forecasts from 2019 to 2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Molybdenum Market - Forecasts from 2019 to 2024" report has been added to ResearchAndMarkets.com's offering.
  • The global Molybdenum market is expected to witness a CAGR of 2.34% to reach US$5.069 billion in 2024, increasing from US$4.411 billion in 2018.
  • Increasing use of molybdenum as a catalyst, filament, pigment, corrosion inhibitor in industries such as petrochemical, electrical and electronics is also driving the market growth.
  • Rising oil prices also affect molybdenum demand positively as it is extensively used in the oil and gas industry.